Navigation Links
drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007
Date:2/6/2008

ational purposes only and

is not prepared in accordance with generally accepted accounting

principles. Adjusted EBITDA is defined as earnings before taxes,

depreciation, and amortization of intangible assets and non-cash

marketing expense, adjusted to exclude the impact of stock-based

compensation expense.

SUPPLEMENTAL INFORMATION: Reconciliation of Forecasted Q1 2008

and FY 2008 Net Income (Loss) Range to Forecasted

Q1 2008 and FY 2008 Adjusted EBITDA Range

Range Calculated As: Three Months Ended Twelve Months Ended

March 30, 2008 December 28, 2008

(In thousands, unless

otherwise indicated) Range High Range Low Range High Range Low

Net income (loss) $(2,350) $(2,850) $3,000 $(1,000)

Amortization of

intangible assets 250 250 900 900

Amortization of

non-cash marketing 575 575 2,300 2,300

Stock-based compensation 2,100 2,100 7,300 7,300

Depreciation 2,225 2,225 10,500 10,500

Interest income, net (400) (400) (2,000) (2,000)

Adjusted EBITDA $2,400 $1,900 $22,000 $18,000

drugstore.com, inc.

Consolidated Balance Sheets

(in thousands, except share data)

December 30, December 31,

2007 2006

(unaudited) (audited)

ASSETS

Current assets:

Cash and cash equivalents $18,572 $13,393

Marketable securities 17,677
'/>"/>

SOURCE drugstore.com, inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. drugstore.com inc. Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007
2. drugstore.com, inc. to Announce Third Quarter 2007 Results During Conference Call on Monday, October 22, 2007 at 5:00 p.m. ET
3. drugstore.com and Revolution Health Group Announce Breakthrough Deal
4. TyraTech Achieves Insecticide Development and Financial Milestones With Partner Arysta LifeScience
5. Joint Commission International Achieves Accreditation from ISQua
6. Cethromycin achieves all endpoints in second pivotal Phase III Trial for treatment for pneumonia
7. Halogen Software Achieves Most Successful Quarter in Company History - Includes Record Year-Over-Year Overall and License Revenue
8. Pharsight Achieves $7.3 Million in Quarterly Revenue
9. ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent
10. LMS integrated obstetrics solution achieves general availability
11. OSF HealthCare Achieves Impressive Tobacco Quit Rates with the Free & Clear(R) Quit For Life(TM) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...ack of the sunlight-derived nutrient tied to incre...ec. 1 (HealthDay News) -- A lack of vitamin D, wh...ight, helps boost the risk of heart attacks and st... array of studies linking increased cardiovascular...H. O,Keefe, director of preventive cardiology at t...
(Date:12/1/2008)...ATLANTA, Dec. 1, 2008 The Arthritis Foundation an...Prize for research in arthritis. The recipients, D...ege of Physicians and Dr. Michel Nussenzweig of Ro...continued research advancements in the cure and co...recognized for his research in the development and...
(Date:12/1/2008)...AIRFAX, Va., Dec. 1 The...ay named Julia E. Bradsher, Ph.D., as its new CEO,...ring. , , Dr. Bradsher brings to FAAN exten...ly fatal allergic reaction. For the past six years...keting team and strategic planning for all Dey Pha...
(Date:12/1/2008)...Dry-needling, steroids effective against plantar ... Dec. 1 (HealthDay News) -- Italian researchers sa...e treatment for the painful foot condition known a...dry-needling" and steroid injections guided by ult...ed a 95 percent success rate in tackling a conditi...
Breaking Medicine News(10 mins):Health News:Vitamin D Vital for the Heart 2Health News:Vitamin D Vital for the Heart 3Health News:FAAN Names New CEO 2Health News:New Twist on Treatment of Foot Pain 2Health News:New Twist on Treatment of Foot Pain 3
...ures are a serious consequence of osteoporosis. Su...,// spinal deformity and hip fracture. According t...ntium ranelate, for women with osteoporosis appear...or a vertebral fracture, according to new research...
...ound exposures during pregnancy may not cause long.../ For the study 2,700 children were evaluated, hal...and half of whom had only one ultrasound exposure ... up at 1, 2, 3, 5 and 8 years of age. While resear...
... young adults who frequently use marijuana may be ... in life //, say researchers based on findings of ...ople between ages 14 and 24 for four years. Partic...predisposition for psychosis, and psychotic sympto...
... shows chronic back pain shrinks the brain by as m...neration of 10 to 20 years of aging.// Using magn...alysis techniques, researchers compared the brain ...ack pain to those of normal participants. The part...
Other Medicine News:
(Date:12/1/2008).../ -- S*BIO Pte Ltd today announced the initiation ...and orally-active JAK2 inhibitor, in leading medic...idiopathic myelofibrosis (CIMF). , , The t...bility of SB1518 in patients with CIMF and is expe... of the study will assess the safety profile and e...
(Date:12/1/2008)...1 gene is a two-way switch that, if turned off, ca...d so that they lose their identity and become more...Tenn., Dec. 1 Scientis...iscovered that a certain differentiated cell type ...s the constant expression of a gene called Prox1 ...
(Date:12/1/2008)...ber 1 Following a,Reque...procure an MVA-based,third generation smallpox v...da, on behalf of the Canadian Department of Nation...rdic for the delivery of IMVAMUNE(R). , The... part of the,country,s bio-preparedness programme...
(Date:12/1/2008)...-FirstCall/ -- Vical Incorporated (Nasdaq: VICL ...lestone payment from Merck & Co., Inc. based o... trial of an investigational plasmid DNA (pDNA) ca...cal,s DNA gene delivery technology and encodes hum... is the subject of separate license agreement. , ...
Breaking Medicine Technology:S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2Algeta Receives IND Approval for Alpharadin 28TM 29 to Commence Clinical Development in the USA 12412 1Algeta Receives IND Approval for Alpharadin 28TM 29 to Commence Clinical Development in the USA 12412 2Algeta Receives IND Approval for Alpharadin 28TM 29 to Commence Clinical Development in the USA 12412 3Federal Health IT Market to Reach 244 5 Billion by 2013 12409 1Federal Health IT Market to Reach 244 5 Billion by 2013 12409 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 1Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 3Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 4Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 5New York Strengthens Emergency Preparedness with Cardinal Health Ventilators 3443 1New York Strengthens Emergency Preparedness with Cardinal Health Ventilators 3443 2
...wswire-FirstCall/ -- Repligen,Corporation announce...rial to evaluate the use of RG1068, synthetic huma...of pancreatic duct,structures by magnetic resonanc...n sensitivity of detection of structural abnormali...ith no loss in,specificity, consistent with prior ...
... WIRE)-May 10, 2007--Today, the,New England Journa... III studies of Merck,s cervical cancer vaccine, G...6, 11, 16, 18),Recombinant Vaccine). In the first ...ainst cervical, vaginal and vulvar diseases,caused...tect,against, HPV types 6, 11, 16, and 18. In the ...
Other Medicine Technology:Repligen Reports Positive Phase 2 Clinical Trial Results of,Secretin for MRI Imaging of the Pancreas 2Repligen Reports Positive Phase 2 Clinical Trial Results of,Secretin for MRI Imaging of the Pancreas 3Repligen Reports Positive Phase 2 Clinical Trial Results of,Secretin for MRI Imaging of the Pancreas 4New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 2New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 3New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 4New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 5New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 6New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 7New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 8New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 9New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 10New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 11New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 12New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 13New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 14New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 15New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 16New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 17New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 18New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 19New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 20New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 21New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 22New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 23New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 24New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 25New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 26New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 27New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 28New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 29New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 30New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 31New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 32
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components
The revision knee system for severe joint deterioration with insufficient ligament support.
The Natural-Knee Family is a complete range of interchangeable, anatomically-designed implants with over 14 years of proven clinical results.
The GENESIS II* Total Knee System will define the state of knee implants.
Medicine Products: